DT-200

DT-200 is an experimental cell therapy candidate currently in the discovery stage, developed by Dystrogen Therapeutics for the treatment of neurodegenerative diseases. It is based on the company's proprietary chimeric cell platform, which involves the creation of chimeric cells designed to address specific disease pathologies. While the platform's lead candidate, DT-DEC01, utilizes Dystrophin Expressing Chimeric (DEC) cells for Duchenne Muscular Dystrophy, DT-200 is a distinct application of this technology targeting the central nervous system. Specific molecular targets and the precise mechanism of action for DT-200 have not yet been publicly disclosed by the developer.